Molecular Partners published Phase 1 data in Nature Cancer showing MP0317, a tumor-localized CD40 agonist, activates immune cells in the tumor microenvironment with a favorable safety profile in advanced cancer patients. The drug anchors to fibroblast activation protein in tumors, potentially improving efficacy and reducing side effects compared to systemic therapies. A Phase 2 trial combining MP0317 with chemotherapy and immunotherapy in cholangiocarcinoma is ongoing to assess clinical benefits. These findings support MP0317's further development in combination cancer treatments.
Uber Technologies Inc. has made a full takeover offer for Delivery Hero at €33 per share, slightly below Delivery Hero's recent closing price. Prior to the offer, Uber increased its stake in Delivery Hero from about 7% to 19.5%, becoming the largest ...
Solana (SOL) is trading around $82, down about 70% from its peak near $295, reflecting weak market demand and significant selling pressure. The critical resistance level at $95 must be surpassed on the weekly chart to trigger a potential relief rally...
Bitcoin dropped to a five-week low of $74,250 before recovering after President Trump announced a largely negotiated peace agreement involving Iran and several Middle Eastern countries. The deal includes reopening the Strait of Hormuz, easing geopoli...
Nasdaq has received approval from the SEC to launch cash-settled Bitcoin index options on the Philadelphia Stock Exchange, using the CME CF Bitcoin Real Time Index as the benchmark. These European-style options settle in cash without actual Bitcoin t...
Intuit is rated overweight with a $560 price target following a 17% workforce reduction and a post-earnings stock selloff that the market misinterpreted. The stock trades at a low multiple of 11 times projected 2027 earnings per share, well below its...
